Every year, pharma loses an estimated $630B on patient non-adherence—but the problem with adherence may not be the message itself, but where the message lands. Pharma invests billions annually in patient outreach: $10B in traditional advertisements, $20B on provider marketing, and an average $21M per drug on promotional efforts aimed at helping patients start and stay on therapy.

Connect 2025 is in the books, and we’re still buzzing about it. Earlier this month, we brought the RedSail Technologies network to Grapevine, TX and proved that everything really is bigger in Texas.

When a clinical message pops up in your pharmacy software—maybe it’s about reminding a patient to get vaccinated for shingles or flagging their 45-day+ gap in therapy—there’s more going on than computerized triggers and drug messaging.

For independent pharmacists, it’s rarely just about the software. Many pharmacists have built their business using PioneerRx, QS/1, or BestRx, and with that comes an expectation: that your technology partner will have your back while continuing to protect your future.

Connect 2025 is right around the corner. Here’s what you need to know and how you can prepare for the RedSail Technology user conference.

As the pharmacy landscape continues to evolve, staying ahead means embracing innovation, expanding your knowledge, and strengthening your professional network. Prepare for your pharmacy’s success by signing up for Connect 2025. From June 5-8 in Grapevine, Texas, the entire RedSail Technologies network will gather under one roof, so why not be a part of it?

Access to healthcare is a growing challenge for many Americans, particularly those in underserved communities and pharmacy deserts. These areas lack the resources needed to support basic healthcare needs, leading to worse health outcomes and higher medical costs.

A lot can happen in a year, and for RedSail Technologies, 2024 has been a transformative and impactful one. From hosting innovative user conferences to expanding our portfolio of offerings, this year has been filled with remarkable milestones that have shaped the future of pharmacy care.

We’ve all seen the news stories about drug compounders filling the gap caused by a shortage of the GLP-1 drugs tirzepatide, Lilly’s Zepbound, and semaglutide, Novo Nordisk’s Wegovy, approved for the treatment of obesity. So, what rules govern how a compounding pharmacy is authorized to legally create a version of a patented drug when the drug is declared to be in short supply?